In a series of papers published in 2005 (10–13), a single point mutation in the pseudokinase domain of JAK2, V617F, was identified in >90% of patients with polycythemia vera and in ~50% of patients with primary myelofibrosis and essential thrombocythemia. This evidence concerns the gene JAK2 and acquired polycythemia vera.